

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

In re application of

Docket No: A8671

Robert Yongxin ZHAO, et al.

Appln. No.: 10/692,856

Group Art Unit: 1626

Confirmation No.: 9247

Examiner: Rei Tsang Shiao

Filed: October 27, 2003

For: IMPROVED PRODRUGS OF CC-1065 ANALOGS

SUBMISSION OF EXECUTED DECLARATION UNDER 37 C.F.R. §1.132

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith is a copy of an executed Declaration Under 37 C.F.R. §1.132 signed
by Walter A. Blättler, Ph.D..

Respectfully submitted,

Drew Hissong
Registration No. 44,765

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: January, 31, 2005



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: A8671

Robert Yongxin ZHAO, et al.

Appln. No.: 10/692,856

Group Art Unit: 1626

Confirmation No.: 9247

Examiner: Rei Tsang Shiao

Filed: October 27, 2003

For: IMPROVED PRODRUGS OF CC-1065 ANALOGS

DECLARATION UNDER 37 C.F.R. § 1.132

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Walter A. Blättler, hereby declare and state:

THAT I am a citizen of Switzerland;

THAT I received an M.S. degree in Chemistry in 1973 from the Swiss Federal Institute of Technology, Zurich (ETH Zürich);

THAT I received a D.sc.nat. in Chemistry in 1978 from the Swiss Federal Institute of Technology, Zurich (ETH Zürich);

THAT I was a Postdoctoral Fellow in the Chemistry Department at Harvard University, Cambridge, MA from 1978-1981;

THAT I was an Associate in Pathology at the Dana Farber Cancer Institute, Harvard Medical School, Boston, MA from 1981-1986;

THAT I was an Assistant Professor in Pathology at the Dana Farber Cancer Institute, Harvard Medical School, Boston, MA from 1986-1987;

THAT I was a Lecturer in Pathology at the Dana Farber Cancer Institute, Harvard Medical School, Boston, MA from 1987-1996;

THAT in 1987 I joined ImmunoGen, Inc. as Vice-President Research, and remained in that position until 1994;

THAT from 1994 to 1996 I was Senior Vice-President, R & D, at ImmunoGen, Inc. Cambridge, MA;

THAT in 1996 I was promoted to Executive Vice President, Science and Technology at ImmunoGen, Inc., Cambridge, MA, and remain in that position today;

A copy of my curricular vitae is attached.

I further declare and state as follows:

I. INTRODUCTION

I am familiar with the Office Action dated October 25, 2005, issued in the above-identified application and with the Examiner's position that the present claims should be limited to reciting analogs of CC-1065 for which specific formulas are identified in the application. Specifically, the Examiner asserts that there is no written description of other CC-1065 analogs. I understand this to mean that the Examiner is asserting that the inventors, of which I am one, did not have possession of other analogs of CC-1065 as of the effective filing date of the present application.

I further understand that the Examiner is asserting that the claims are not enabled for a prodrug of an analog of CC-1065, wherein the analog is not one specifically defined by a formula in the specification. I understand this to mean that the Examiner believes that one of

ordinary skill in the art would not have known how to make and use prodrugs of other analogs of CC-1065 as of the effective filing date of the present application.

For the following reasons, the Examiner's position is at odds with the state of the art as it existed at the time of the effective filing date of the present application.

II. THE APPLICATION CONTAINS A WRITTEN DESCRIPTION OF A BROAD GROUP OF CC-1065 ANALOGS AND PRODRUGS THEREOF

There are many published reports (as examples see the list of references given) describing the preparation of CC-1065 analogues. Therefore this class of compounds is well defined.

The natural cytotoxic antibiotic CC-1065 is composed of two structural elements with separate functions. The CPI element (cyclopropa[c]pyrrolo[3.2-e]indol-4(5H)-one element) covalently alkylates DNA and the element containing two benzo[1,2-b:4,3-b']dipyrrole moieties binds to DNA. When CC-1065 was tested in animals it caused delayed lethality, which prevented its use in humans. A quote from ref. 8, first page, second paragraph: "To pursue compounds retaining the potent antitumor activity but devoid of the toxic side effects of the parent compound, many CC-1065 analogues have been synthesized and tested." To retain the potent antitumor activity, the two functions, i.e. DNA alkylation found in the first element, and the DNA binding function found in the second element, had to be retained. Therefore CC-1065 analogues will mimic the CPI element and the benzodipyrrole element.

The first set of analogs published (ref. 1) altered the binding element but retained the CPI element. A second series changed the CPI element (cyclopropa[c]pyrrolo[3.2-e]indol-4(5H)-one

element) to the CBI element (cyclopropa[c]benz[e]indole-4-one element), carefully preserving the cyclopropa-indole-4-one moiety, which is the inherent alkylating activity (ref. 3).

Therefore as of the effective filing date of the above-identified application and currently, one of ordinary skill in the art, which includes the present inventors, readily recogniz(ed) analogs of CC-1065 as compounds that contain a cyclopropa-indole-4-one alkylating moiety, such as CPI or CBI, and a DNA binding element containing ring structures and that any of these compounds could be the CC-1065 analogs of the claimed prodrugs.

References with titles included.

- 1) M.A. Warpehoski, I. Gebhard, R.C. Kelly, W.C. Krueger, L.H. Li, J.P. McGovren, M.D. Prairie, N. Wicnienski, and W. Wierenga: Stereoelectronic factors influencing the biological activity and DNA interaction of synthetic antitumor agents modeled on CC-1065. *J. Med. Chem.* 31, 590-603 (1988).
- 2) D.L. Boger and S.A. Munk: DNA alkylation properties of enhanced functional analogs of CC-1065 incorporating the 1,2,9,9a-Tetrahydrocyclopropa[1,2-c]benz[1,2-e]indol-4-one (CBI) alkylation subunit. *J. Am. Chem. Soc.* 114(14), 5487-5496 (1992).
- 3) D.L. Boger, W. Yun, and B.R. Teegarden: An improved synthesis of 1,2,9,9a-Tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI): a simplified analogue of the CC-1065 alkylation subunit. *J. Org. Chem.* 57, 2873-2876 (1992).
- 4) D.L. Boger and M.S.S. Palanki: Functional analogs of CC-1065 and the duocarmycins incorporating the 9a-(Chloromethyl)-1,2,9,9a-Tetrahydrocyclopropa[c]benz[e]indol-4-one (C₂BI) alkylation subunit: synthesis and preliminary DNA alkylation studies. *J. Am. Chem. Soc.* 114, 9318-9327 (1992).

- 5) D.L. Boger, D.S. Johnson, M.S.S. Palanki: Evaluation of functional analogs of CC-1065 and the duocarmycins incorporating the cross-linking 9a-(Chloromethyl)-1,2,9,9a-Tetrahydrocyclopropa[c]benz[e]indol-4-one (C₂BI) alkylation subunit. *Bioorg. & Med. Chem.* 1(1), 27-38 (1993).
- 6) D.L. Boger and D.S. Johnson: CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents. *Proc. Natl. Acad. Sci. USA* 92, 3642-3649 (1995).
- 7) D.L. Boger, N. Han, C.M. Tarby, C. W. Boyce, H. Cai, Q. Jin, and P.A. Kitos: Synthesis, chemical properties, and preliminary evaluation of substituted CBI analogs of CC-1065 and the duocarmycins incorporating the 7-Cyano-1,2,9,9a-Tetrahydrocyclopropa[c]benz[e]indol-4-one alkylation subunit: Hammett quantitation of the magnitude of electronic effects on functional reactivity. *J. Org. Chem.* 61, 4894-4912 (1996).
- 8) Y. Wang, H. Yuan, W. Ye, S.C. Wright, H. Wang, and J.W. Larrick: Synthesis and preliminary biological evaluations of CC-1065 analogues: effects of different linkers and terminal amides on biological activity. *J. Med. Chem.* 43, 1541-1549 (2000).
- 9) D.L. Boger: Synthesis of CC-1065/Duocarmycin analogs. US Patent No. 6,310,209 B1, issued October 30, 2001.
- 10) M.J. Powell: Cyclopropylindole prodrugs. US Patent No. 5,646,298, issued July 8, 1997.

**III. THE APPLICATION TEACHES ONE OF ORDINARY SKILL IN THE ART
HOW TO MAKE AND USE A BROAD GROUP OF CC-1065 ANALOGS AND
PRODRUGS THEREOF**

CC-1065 is one of a few classes of extremely potent antitumor agents. It binds to double-stranded B-DNA within the minor groove with a sequence preference for 5'-d(A/GNTTA)-3' and 5'-d(AAAAA)-3', and alkylates the N3 position of the 3'-adenine with its left-hand CPI segment. CC-1065 also inhibits gene transcription by interfering with binding of the TATA box-binding protein to its target DNA. Despite its high potency and broad spectrum of antitumor activity, CC-1065 cannot be used in humans because it showed delayed, severe toxicity in experimental animals. Administration of CC-1065 to mice caused delayed hepatotoxicity leading to mortality on day 50 after a single intravenous dose of 12.5 µg/kg (1986, V. L. Reynolds et al., *J. Antibiotics*, **XXIX**, 319-334).

This spurred efforts to develop analogs that preserve the broad spectrum of antitumor activity but are devoid of the delayed toxicity. The synthesis and characterization of many such analogs modeled on CC-1065 was first described by M.A. Warpehoski et al. (1988, *J. Med. Chem.*, **31**:590-603. *Stereoelectronic factors influencing the biological activity and DNA interaction of synthetic antitumor agents modeled on CC-1065*) (ref. 1, cited above). In a second series of such analogs, the CPI or seco-CPI moiety of CC-1065 analogs was replaced by a cyclopropabenzindole (CBI) moiety or a seco-CBI moiety (1990, D.L. Boger et al., *J. Org. Chem.*, **55**:5823-5833, *Functional analogs of CC-1065 and the duocarmycins incorporating the 1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) left-handed subunit*; 1991, D.L. Boger et al., *BioOrg. Med. Chem. Lett.*, **1**:115-120, *Synthesis and preliminary evaluation of (+)-CBI-indole₂: an enhanced functional analog of (+)-CC-1065*; U.S. patent No. 6,060,608). These

compounds maintain the high *in vitro* potency of the parental drug, without causing delayed toxicity in mice. Like CC-1065, these compounds are alkylating agents that bind to the minor groove of DNA in a covalent manner to cause cell death. However, clinical evaluation of the most promising analogs, Adozelesin and Carzelesin, has led to disappointing results (1996, B.F. Foster et al., *Investigational New Drugs*, 13:321-326 ; 1996, I. Wolff et al., *Clin. Cancer Res.*, 2:1717-1723). These drugs display poor therapeutic effects because of their high systemic toxicity.

To enhance the therapeutic efficacy of CC-1065 analog drugs, ImmunoGen, Inc., the assignee of the above-identified application, then prepared analogs of CC-1065 that could be chemically linked to a cell-binding agent. This enabled the preparation of novel cell-binding agent-drug conjugates for the targeted delivery of the cytotoxic agent to specific cell populations. (see e.g. U.S. patent No. 5,846,545). These analogs of CC-1065 contain a moiety at the terminal amide that allows chemical linkage to the cell-binding agent (see e.g. Figures 3 to 6 in U.S. patent No. 5,846,545). Such analogs with different substituents at the terminal amide were not only prepared by scientists at ImmunoGen, Inc., but also by other scientists, such as Wang Y. et al. (2000, *J Med Chem.*, 43:1541-1549, *Synthesis and preliminary biological evaluation of CC-1065 analogues: Effects of different linkers and terminal amides on biological activity*).

Therefore, the preparation of numerous compounds classified as CC-1065 analogs that can be used to make the prodrugs of the present claims is described in many scientific publications and is routine for one skilled in the art.

The instant application improves on the CC-1065 analogs described above by the formation of prodrugs of such CC-1065 analogs that can be linked to cell-binding agents.

Prodrug formation serves to increase the solubility in aqueous solutions and to stabilize the seco-CBI moiety of the CC-1065 analogs through the reaction of the phenolic hydroxyl group to introduce a protecting group.

The design and preparation of prodrugs is a well-known and described science. (see e.g. 2003, Bernard Testa & Joachim M. Mayer, *Hydrolysis in Drug and Prodrug Metabolism, Chemistry, Biochemistry, and Enzymology*, Wiley-VCH, Zurich, Chapter 1.2. *Principle of Prodrug Design*; Chapter 8. *Hydrolysis of Carboxylic Acid Ester Prodrugs*; Chapter 8.4. *Prodrugs of Active Alcohols and Phenols*; Chapter 9. *The Cleavage of Esters of Inorganic Acids*; Chapter 9.3. *Hydrolysis and Oxidative Cleavage of Organophosphates*; Chapter 9.3.2. *Hydrolysis of Medicinal Phosphoric Acid Alkyl and Aryl Monoesters*). The prodrugs described in the instant application are prodrugs of an active phenol, therefore some chapters in the above reference book that specifically deal with such prodrugs are mentioned. Also there are many prodrugs of active phenols known, such as irinotecan·HCl, which is a water-soluble dipiperidinylcarbamate prodrug of the active phenol, camptothecin, etopophos is a water-soluble phosphoryl mono ester prodrug of the phenol drug, etoposide, aspirine is an ester prodrug of the phenol drug, salicylic acid, and estradiol acetate is an ester prodrug of the phenol drug, estradiol.

Therefore the preparation of phenol prodrugs with the appropriate characteristics is well studied and described in the scientific literature and is routine for one skilled in medicinal chemistry.

Accordingly, as of the effective filing date of the above-identified application, one of ordinary skill in the art could readily have made the claimed prodrugs from a variety of CC-1065 analogues.


Declaration Under 37 C.F.R. § 1.132
U.S. Application No. 10/692,856


A8671

I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date:

Jan. 31, 2005


Walter A. Blättler, Ph.D.



Curriculum Vitae

Walter A. Blättler
197 Mason Terrace
Brookline, MA 02146
Tel.: (617) 566-1171

Executive Vice President, Science &
Technology
ImmunoGen, Inc.
128 Sidney Street
Cambridge, MA 02139
Tel: (617) 995-2500, Fax: (617) 995-2510

Education:

Swiss Federal Institute of Technology, Zurich (ETH Zürich)	M.S.	1973	Chemistry
Swiss Federal Institute of Technology, Zurich (ETH Zürich)	Dr.sc.nat.	1978	Chemistry

Research and Professional Experience:

1978 - 1981	Postdoctoral Fellow, Chemistry Department, Harvard University, Cambridge, MA
1981 - 1986	Associate in Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
1986 - 1987	Assistant Professor in Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
1987 - 1996	Lecturer in Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
1987 - 1994	Vice-President Research, ImmunoGen, Inc., Cambridge, MA
1994 - 1996	Senior Vice President, R & D, ImmunoGen, Inc., Cambridge, MA
1996 -	Executive Vice President, Science & Technology, ImmunoGen, Inc., Cambridge, MA

Publications:

1978

Blättler, W.A. (1978) Sterischer Verlauf der Bildung und Öffnung des Cyclopropanringes in der Biosynthese von Phytosterinen. Thesis, ETH, Zürich.

1979

Blättler, W.A. and Knowles, J.R. (1979) Stereochemical course of glycerol kinase, pyruvate kinase, and hexokinase: phosphoryl transfer from chiral [(-S)-¹⁶O, ¹⁷O, ¹⁸O]ATP. *J. Am. Chem. Soc.* 101, 510-511.

Blättler, W.A. and Knowles, J.R. (1979) Stereochemical course of phosphokinases. The use of adenosine [(-S)-¹⁶O, ¹⁷O, ¹⁸O]triphosphate and the mechanistic consequences for the reactions catalyzed by glycerol kinase, hexokinase, pyruvate kinase, and acetate kinase. *Biochem. 18*, 3927-3933.

1980

Blättler, W.A. and Knowles, J.R. (1980) Phosphoglycerate mutases: stereochemical course of the phosphoryl group transfers catalyzed by the cofactor-dependent enzyme from rabbit muscle and the cofactor-independent enzyme from wheat germ. *Biochem. 19*, 738-743.

1982

Hassett, A., Blättler, W.A., and Knowles, J.R. (1982) Pyruvate Kinase: Is the mechanism of Phospho transfer associative or dissociative? *Biochem. 21*, 6335-6340.

1985

Blättler, W.A., Kuenzi, B.S., Lambert J.M., and Senter, P.D. (1985) New heterobifunctional protein cross-linking reagent that forms an acid-labile link. *Biochem. 24*, 1517-1524.

Senter, P.D., Tansey, M.J., Lambert, J.M., and Blättler, W.A. (1985) Novel photocleavable protein cross-linking reagents and their use in the preparation of antibody-toxin conjugates. *Photochem. and Photobiol. 42*, 231-237.

Lambert, J.M., Senter, P.D., Yau-Young, A., Blättler, W.A., and Goldmacher, V.S. (1985) Purified immunotoxins that are reactive with human lymphoid cells,. *J. Biol. Chem. 260*, 12035-12041.

Goldmacher, V.S., Anderson, J., Blättler, W.A., Lambert, J.M., and Senter, P.D. (1985) Antibody-complement-mediated cytotoxicity is enhanced by ribosome-inactivating proteins. *J. Immunol. 135*, 3648-3651.

1986

Goldmacher, V.S., Lambert, J.M., Yau-Young, A., Anderson, J., Tinnel, N.L., Kurnacki, N.K., Ritz, J., and Blättler, W.A. (1986) Expression of the common acute lymphoblastic leukemia antigen (CALLA) on the surface of individual cells in human lymphoblastoid lines. *J. Immunol. 136*, 320-325.

1987

Goldmacher, V.S., Anderson, J., Schulz, M-L., Blättler, W.A., and Lambert, J.M. (1987) Somatic cell mutants resistant to ricin, diphtheria toxin and immunotoxins. *J. Biol. Chem. 262*, 3205-3209.

Scott, C.F., Jr., Lambert, J.M., Goldmacher, V.S., Blättler, W.A., Sobel, R., Schlossman, S.F., and Benacerraf, B. (1987) The pharmacokinetics and toxicity of murine monoclonal antibodies and of gelonin conjugates of these antibodies. *Int. J. Immunopharmac.* 9, 211-215.

Scott, C.F., Jr., Goldmacher, V.S., Lambert, J.M., Chari, R.V.J., Bolender, S., Gauthier, M.N., and Blättler, W.A. (1987) The anti-leukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy1-1 antibody disulfide-linked to the ribosome-inactivating protein, gelonin. *Cancer Immunol. Immunother.* 25, 31-40.

Moroney, S.F., D'Alarcao, L.J., Goldmacher, V.S., Lambert, J.M., and Blättler, W.A. (1987) Modification of the binding site(s) of lectins by an affinity column carrying an activated galactose-terminated ligand. *Biochem.* 26, 8390-8398.

1988

Scott, C.F., Jr., Lambert, J.M., Bolender, S., and Blättler, W.A. (1988) Resting human peripheral blood lymphocytes can be activated to cytolytic function by antibodies to CD3 in the absence of exogenous interleukin-2. *Cell. Immunol.* 114, 370-384.

Scott, C.F., Jr., Blättler, W.A., Lambert, J.M., Kalish, R.S., Morimoto, C., and Schlossman, S.F. (1988) Requirements for the construction of antibody heterodimers for the direction of lysis of tumors by human T cells. *J. Clin. Invest.* 81, 1427-1433.

Lambert, J.M. and Blättler, W.A. (1988) Purification and biochemical characterization of immunotoxins. In *Immunotoxins*. (A.E. Frankel, Ed.), Nijhoff, Boston, 323-348.

Lambert, J.M., Blättler, W.A., McIntyre, G.D., Goldmacher, V.S., and Scott, C.F., Jr. (1988) Immunotoxins containing single chain ribosome-inactivating proteins. In *Immunotoxins*. (A.E. Frankel, Ed.), Nijhoff, Boston, 175-209.

1989

Goldmacher, V.S., Blättler, W.A., Lambert, J.M., McIntyre, G., and Stewart, J. (1989) Cytotoxicity of gelonin conjugated to targeting molecules: Effects of weak amines, monensin, adenovirus, and adenoviral capsid proteins penton, hexon, and fiber. *Mol. Pharm.* 36, 818-822.

Goldmacher, V.S., Scott, C.F., Jr., Lambert, J.M., McIntyre, G., Blättler, W.A., Collinson, A.R., Stewart, J., Chong, L.D., Cook, S., Slayter, H.S., Beaumont, E., and Watkins, S. (1989) Cytotoxicity of Gelonin and its conjugates with antibodies is determined by the extent of their endocytosis. *J. Cell. Physiol.* 141, 222-234.

Blättler, W.A., Lambert, J.M., and Goldmacher, V.S. (1989) Realizing the full potential of immunotoxins. *Cancer Cells* 1, 50-55.

1991

Lambert, J.M., McIntyre, G., Gauthier, M.N., Zullo, D., Rao, V., Steeves, R.M., Goldmacher, V.S., and Blättler, W.A. (1991) The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligand prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides. *Biochem.* 30, 3234-3247.

Roy, D.C., Griffin, J.D., Belvin, M., Blättler, W.A., Lambert, J.M., and Ritz, J. (1991) Anti-MY9-Blocked Ricin: An Immunotoxin for selective targeting of acute myeloid leukemia cells. *Blood* 77, 2404-2412.

Lambert, J.M., Goldmacher, V.S., Collinson, A.R., Nadler, L.M., and Blättler, W.A. (1991) An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. *Cancer Res.* 51, 6236-6242.

1992

La Russa, V.F., Griffin, J.D., Kessler, S.W., Cutting, M.A., Knight, R.D., Blättler, W.A., Lambert, J.M., and Wright, D.G. (1992) Anti-CD33 immunotoxin and human hematopoietic progenitors. *Exp. Hematol.* 20, 442-448.

Chari, R.V.J., Martell, B.A., Gross, J.L., Cook, S.B., Shah, S.A., Blättler, W.A., McKenzie, S.J., and Goldmacher, V.S. (1992) Immunoconjugates containing novel maytansinoids: promising anti-cancer drugs. *Cancer Res.* 52, 127-131.

Grossbard, M.L., Freedman, A.S., Ritz, J., Coral, F., Goldmacher, V.S., Eliseo, L., Spector, N., Dear, K., Lambert, J.M., Blättler, W.A., Taylor, J.A., and Nadler, L.M. (1992) Serotherapy of B-cell neoplasms with anti-b4-blocked ricin: A phase I trial of daily bolus infusion. *Blood* 79, 576-585.

Goldmacher, V.S., Lambert, J.M., and Blättler, W.A. (1992) The specific cytotoxicity of immunoconjugates containing blocked ricin is dependent on the residual binding capacity of blocked ricin: evidence that the membrane binding and A-chain translocation activities of ricin cannot be separated. *Biochem., Biophys. Res. Commun.* 183, 758-765.

Streuli, M., Krueger, N.X., Ariniello, P.D., Tang, M., Munro, J.M., Blättler, W.A., Adler, D.A., Distech, C.M., and Saito, H. (1992) Expression of the receptor linked protein tyrosine phosphatase LAR: proteolytic cleavage and shedding of the CAM-like extracellular region: *EMBO* 11, 897-907.

Goldmacher, V.S., Senter, P.D., Lambert, J.M., and Blättler, W.A. (1992) Photoactivation of toxin conjugates. *Bioconjugate Chem.* 3, 104-107.

Swimmer, C., Lehar, S.M., McCafferty, J., Chiswell, D.J., Blättler, W.A., and Guild, B.C. (1992) Phage display of ricin B chain and its single binding domains: System for screening galactose-binding mutants. *Proc. Natl. Acad. Sci. USA.* 89, 3756-3760.

Grossbard, M.L., Lambert, J.M., Goldmacher, V.S., Blättler, W.A., and Nadler, L.M. (1992) Correlation between *in vivo* toxicity and preclinical *in vitro* parameters for the immunotoxin Anti-B4-Blocked Ricin. *Cancer Res.* 52, 4200-4207.

1993

Grossbard, M.L., Lambert, J.M., Goldmacher, V.S., Freedman, A.S., Kinsella, J., Ducello, D.P., Rabinowe, S.N., Elisea, L., Coral, F., Taylor, J.A., Blättler, W.A., Epstein, C.L., and Nadler, L.M. (1993) Anti-b4-blocked Ricin: A phase I trial of 7 day continuous infusion in patients with B-cell neoplasms. *J. Clin. Oncol.* 11, 726-737.

Grossbard, M.L., Gribben, J.G., Freedman, A.S., Lambert, J.M., Kinsella, J., Rabinowe, S.N., Elisea, L., Taylor, J.A., Blättler, W.A., Epstein, C.L., and Nadler, L.M. (1993) Adjuvant immunotoxin therapy with Anti-B4-Blocked Ricin following autologous bone marrow transplantation for patients with B-cell Non-Hodgkin's lymphoma. *Blood* 81, 2263-2271.

Shah, S.A., Halloran, P.M., Ferris, C.A., Levine, B.A., Bourret, L.A., Goldmacher, V.S., and Blättler, W.A. (1993) Anti-B4-Blocked Ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. *Cancer Res.* 53, 1360-1367.

Singh, R., Blättler, W.A., and Collinson, A.R. (1993) An amplified assay for thiols based on reactivation of papain. *Anal. Biochem.* 213, 49-56.

Shah, S.A., Lambert, J.M., Goldmacher, V.S., Esber, H.J., Levin, J.L., Chungi, V., Zutshi, A., Braman, G.M., Ariniello, P.D., Taylor, J.A., and Blättler, W.A. (1993) Evaluation of the systemic toxicity and pharmacokinetics of the immunoconjugate Anti-B4-Blocked Ricin in non-human primates, delivered by multiple bolus injections and by continuous infusion. *Int. J. Immunopharmac.* 15, 723-736.

1994

Roguska, M.A., Pedersen, J.T., Keddy, C.A., Henry, A.H., Searle, S.J., Lambert, J.M., Goldmacher, V.S., Blättler, W.A., Rees, A.R., and Guild, B.C. (1994) Humanization of murine monoclonal antibodies through variable domain resurfacing. *Proc. Natl. Acad. Sci. USA.* 91, 969-973.

McIntyre, G.D., Scott, C.F., Jr., Ritz, J., Blättler, W.A., and Lambert, J.M. (1994) Preparation and characterization of interleukin-2-gelolin conjugates made using different cross-linking reagents. *Bioconjugate Chem.* 5, 88-97.

Lehar, S.M., Pedersen, J.T., Kamath, R.S., Swimmer, C., Goldmacher, V.S., Lambert, J.M., Blättler, W.A., and Guild, B.C. (1994) Mutational and structural analysis of the lectin activity in binding domain 2 of ricin B chain. *Prot. Eng.* 7, 1261-1266.

1995

Roy, D.C., Perreault, C., Bélanger, R., Gyger, M., Le Houillier, C., Blättler, W.A., Lambert, J.M., and Ritz, J. (1995) Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using Anti-B4-blocked-ricin immunotoxin. *J. Clin. Immunol.* 15.

Krek, C.E., Ladino, C.A., Goldmacher, V.S., Blättler, W.A., and Guild, B.C. (1995) Expression and secretion of a recombinant ricin immunotoxin from murine myeloma cells. *Prot. Eng.* 8, 481-489.

Singh, R., Blättler, W.A., and Collinson, A.R. (1995) Assay for thiols based on reactivation of papain. *Methods in Enzymol.* 251, 229-237.

Chari, R.V.J., Jackel, K.A., Bourret, L.A., Derr, S.M., Tadayoni, B.M., Mattocks, K.M., Shah, S.A., Liu, C., Blättler, W.A., and Goldmacher, V.S. (1995) Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation. *Cancer Res.* 55, 4079-4084.

O'Connor, R., Liu, C., Ferris, C.A., Guild, B.C., Teicher, B.A., Corvi, C., Liu, Y., Arceci, R.J., Goldmacher, V.S., Lambert, J.M., and Blättler, W.A. (1995) Anti-B4-Blocked Ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. *Blood* 86, 4286-4294.

1996

Liu, C., Lambert, J.M., Teicher, B.A., Blättler, W.A., and O'Connor, R. (1996) Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs. *Blood* 87, 3892-3898.

Singh, R., Kats, L., Blättler, W.A., and Lambert, J.M. (1996) Formation of N-Substituted 2-Iminothiolanes when amino groups in proteins and peptides are modified by 2-Iminothiolane. *Anal. Biochem.* 236, 114-125.

Liu, C., Tadayoni, B.M., Bourret, L.A., Mattocks, K.M., Derr, S.M., Widdison, W.C., Kedersha, N.L., Ariniello, P.D., Goldmacher, V.S., Lambert, J.M., Blättler, W.A., and Chari, R.V.J. (1996) Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. *Proc. Natl. Acad. Sci. USA* 93, 8618-8623.

Roguska, M.A., Pedersen, J.T., Henry, A.H., Roja, C.M., Avery, B., Hoffee, M., Cook, S., Lambert, J.M., Blättler, W.A., Rees, A.R., and Guild, B.C. (1996) A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing. *Protein Eng.* 9, 895-904.

Blättler, W.A., Chari, R.V.J., and Lambert, J.M. (1996) Immunoconjugates. In *Cancer Therapeutics: Experimental and Clinical Agents*. (B. Teicher Humana Press Inc., Ed.) Totowa, NJ, Vol. 17 pp. 371-394.

1997

O'Connor, R., Kauffman-Zeh, A., Liu, Y., Lehar, S., Evan, G.I., Baserga, R., and Blättler, W.A. (1997) Identification of domains of the insulin-like growth factor I receptor that are required for protection from Apoptosis. *Mol. and Cell. Biol.* 17, 427-435.

Lynch, Jr., T.J., Coral, F., Shefner, J., Wen, P., Blättler, W.A., Lambert, J.M., Collinson, A.R., Ariniello, P., Braman, G., Cook, S., Esseltine, D., Elias, A., Skarin, A., and Ritz, J. (1997) N901-blocked ricin in small lung cancer: A phase I study. *J. Clin. Oncol.* 15, 723-734.

1998

Blättler, W.A. and Lambert, J.M. (1998) Preclinical immunotoxin development. In *Monoclonal Antibody-Based Therapy of Cancer* (M. Grossbard, Ed.), Marcel Dekker, Inc. NY, NY, pp. 1-22.

Grossbard, M.L., Fidas, P., Kinsella, J., O'Toole, J., Lambert, J.M., Blättler, W.A., Esseltine, D., Braman, G., Nadler, L.M., and Anderson, K.C. (1998) Anti-B4-blocked ricin: a phase II trial of 7-day continuous infusion in patients with multiple myeloma. *British J. Haematol.* 102, 509-515.

2001

Blättler, W.A. and Chari, R. (2001) Drugs to enhance the therapeutic potency of anti-cancer antibodies: antibody-drug conjugates as tumor-activated prodrugs. In *Anticancer Agents - Frontiers in Cancer Chemotherapy* (Iwao Ojima, Gregory D. Vite, Karl-Heinz Altmann, Eds.), American Chemical Society, pp. 317-338.

2002

Goldmacher, V.S., Blättler, W.A., Lambert, J.M., and Chari, R.V.J. (2002) Immunotoxins and antibody-drug conjugates for cancer treatment. In *Biomedical Aspects of Drug Targeting* (V. Muzykantov and V. Torchilin, Eds.), Kluwer Academic Publishers, 291-309.

2003

Maloney, E.K., McLaughlin, J.L., Dagdigian, N.E., Garrett, L.M., Connors, K.M., Zhou, X.M., Blättler, W.A., Chittenden, T., and Singh, R. (2003) An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. *Cancer Res.* 63, 5073-5083.

2004

Xie, H., Audette C., Mary Hoffee, Lambert, J.M., and Blättler, W.A.: Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1),

and its two components in mice. *J. Pharmacology and Experimental Therapeutics* 308, 1073-1082 (2004).